dextromethorphan/quinidine — United Healthcare
pseudobulbar affect
Initial criteria
- Diagnosis of pseudobulbar affect
Reauthorization criteria
- Documentation of positive clinical response to therapy
Approval duration
12 months
pseudobulbar affect
12 months